Results 61 to 70 of about 1,438,395 (306)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Innovation and firm performance [PDF]

open access: yes
Understanding the relation between innovation and performance in both large, medium, and small firms is of crucial importance for ongoing economic growth, but still hardly understood.
Jeroen de Jong   +3 more
core   +3 more sources

State Ownership and Firm Performance: Evidence From the Chinese Listed Firms

open access: yesOrganizations and Markets in Emerging Economies, 2011
Based on a sample of Chinese listed firms, this paper seeks to understand the role of state ownership on firm performance (accounting-based returns) and firm value (market-based indicators). Results show that state ownership is positively associated with
Trien Le, Amon Chizema
doaj   +1 more source

Corporate Cash Holdings and Firm Performance in India: An Empirical Investigation of the Effects of Audit Quality and Firm Growth

open access: yesAmerican Business Review, 2023
This paper examines the effects of audit quality and firm growth on the relationship between corporate cash holdings and firm performance by using a sample of about 2500 unique non-financial Indian firms from 2000 to 2017, consisting of 51,388 firm-year ...
Nirosha Hewa Wellalage   +2 more
doaj   +1 more source

The View from the Top: How Strategic Human Resource Management Affects the Performance of Initial Public Offering Firms [PDF]

open access: yes, 1997
We study SHRM by taking an organizational level perspective on control over all employees. Drawing from agency theory, control theory, and the resource-based view of the firm, we develop hypotheses regarding the differential effects on firm performance ...
Cyr, Linda A., Welbourne , Theresa M.
core   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Regulation and firm perception, eco‐innovation and firm performance [PDF]

open access: yesEuropean Journal of Innovation Management, 2012
PurposeRecent reports argue that eco‐innovation is the key to realising growth. The purpose of this paper is to examine the factors which drive eco‐innovation and test if eco‐innovating firms perform better than non‐eco‐innovating firms. The paper provides insights into the role government regulation can play in directing and stimulating eco‐innovation.
Doran, Justin, Ryan, Geraldine
openaire   +3 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

The Determinants and Outcomes of Forward-Looking Disclosure Evidence from Companies listed in Indonesia [PDF]

open access: yes, 2017
The aim of the study was to examine the determinants and outcomes of forward-looking disclosure. The determinants of forward-looking disclosure were solvability, profitability, liquidity, firm size, and sector type.
HARTO, Puji, ZHAFARINA, Dilla
core  

Home - About - Disclaimer - Privacy